Holen Sie sich die Stockscreener-App
19.71
3.63%
0.69
Schlusskurs vom Vortag:
$19.02
Offen:
$18.93
24-Stunden-Volumen:
297.39K
Relative Volume:
0.87
Marktkapitalisierung:
$799.61M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-136.98M
KGV:
-4.903
EPS:
-4.02
Netto-Cashflow:
$-126.63M
1W Leistung:
-2.38%
1M Leistung:
+16.28%
6M Leistung:
-12.20%
1J Leistung:
-17.15%
1-Tages-Spanne:
$18.93
$19.78
1-Wochen-Bereich:
$18.35
$20.99
52-Wochen-Spanne:
$15.47
$36.37
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Firmenname
Arrivent Biopharma Inc
Sektor
Branche
Telefon
240-780-6356
Adresse
18 CAMPUS BLVD., NEWTOWN SQUARE
Vergleichen Sie AVBP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
19.71 | 765.54M | 0 | -136.98M | -126.63M | -4.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2025-03-20 | Eingeleitet | B. Riley Securities | Buy |
| 2025-03-10 | Eingeleitet | Guggenheim | Buy |
| 2024-07-22 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-02-20 | Eingeleitet | Citigroup | Buy |
| 2024-02-20 | Eingeleitet | Goldman | Buy |
| 2024-02-20 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Arrivent Biopharma Inc Aktie (AVBP) Neueste Nachrichten
Infinitum Asset Management LLC Has $38.21 Million Stock Position in ArriVent BioPharma, Inc. $AVBP - MarketBeat
Applying sector rotation models to ArriVent BioPharma Inc.Gold Moves & Fast Exit Strategy with Risk Control - Newser
Exit strategy if you’re trapped in ArriVent BioPharma Inc.Market Activity Summary & Safe Entry Point Alerts - Newser
Risk vs reward if holding onto ArriVent BioPharma Inc.July 2025 Update & AI Optimized Trading Strategy Guides - Newser
Is this a good reentry point in ArriVent BioPharma Inc.Trade Entry Summary & Precise Buy Zone Identification - Newser
How high can ArriVent BioPharma Inc. stock goGap Down & Comprehensive Market Scan Insights - Newser
Developing predictive dashboards with ArriVent BioPharma Inc. dataQuarterly Portfolio Review & Free Low Drawdown Momentum Trade Ideas - Newser
Will breakout in ArriVent BioPharma Inc. lead to full recoveryJuly 2025 Volume & Fast Moving Market Watchlists - Newser
What to expect from ArriVent BioPharma Inc. in the next 30 daysProfit Target & Growth Focused Entry Point Reports - Newser
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 4.7%Here's Why - MarketBeat
What’s next for ArriVent BioPharma Inc. stock priceWeekly Gains Report & Capital Efficiency Focused Strategies - Newser
Regression analysis insights on ArriVent BioPharma Inc. performanceJuly 2025 Catalysts & Weekly High Momentum Picks - Newser
Institutional scanner results for ArriVent BioPharma Inc.Portfolio Risk Report & AI Driven Price Predictions - Newser
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Average Rating of "Buy" from Brokerages - MarketBeat
How to monitor ArriVent BioPharma Inc. with trend dashboards2025 Risk Factors & Weekly Setup with ROI Potential - Newser
Advanced analytics toolkit walkthrough for ArriVent BioPharma Inc.July 2025 Spike Watch & Long-Term Safe Return Strategies - Newser
Will ArriVent BioPharma Inc. stock go up soonWall Street Watch & Weekly Consistent Profit Watchlists - Newser
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Average Rating of “Buy” from Brokerages - Defense World
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
ArriVent Biopharma presents proof-of-concept data from Phase 1b FURTHER trial - MSN
Will ArriVent BioPharma Inc. benefit from macro trendsPortfolio Gains Summary & Reliable Price Breakout Alerts - Newser
What MACD and RSI say about ArriVent BioPharma Inc.July 2025 WrapUp & Precise Entry and Exit Recommendations - Newser
Intraday pattern recognizer results for ArriVent BioPharma Inc.Earnings Recap Summary & Fast Entry High Yield Stock Tips - Newser
how to monitor arrivent biopharma inc. with trend dashboardsJuly 2025 Macro Moves & Weekly Consistent Profit Watchlists - Newser
Is ArriVent BioPharma Inc. stock bottoming out2025 Market Overview & Smart Allocation Stock Reports - Newser
ArriVent reports 16-month PFS for lung cancer drug firmonertinib - Investing.com
ArriVent BioPharma Reports Positive Phase 1b Results for Firmonertinib in EGFR PACC Mutant NSCLC, Anticipates Phase 3 ALPACCA Study Enrollment in 2025 - Quiver Quantitative
16-Month Survival Breakthrough: ArriVent's New Lung Cancer Drug Shows Promising CNS Response in Global Trial - Stock Titan
Analyzing recovery setups for ArriVent BioPharma Inc. investors2025 Breakouts & Breakdowns & Smart Allocation Stock Tips - Newser
developing predictive dashboards with arrivent biopharma inc. dataVolume Spike & Proven Capital Preservation Methods - Newser
Real time breakdown of ArriVent BioPharma Inc. stock performance2025 Trade Ideas & High Win Rate Trade Tips - Newser
Should I buy ArriVent BioPharma Inc. stock now2025 Key Lessons & Safe Capital Investment Plans - beatles.ru
Finanzdaten der Arrivent Biopharma Inc-Aktie (AVBP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Arrivent Biopharma Inc-Aktie (AVBP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| LaChapelle Robin | Chief Operating Officer |
Sep 19 '24 |
Option Exercise |
3.28 |
27,566 |
90,481 |
124,583 |
0.93%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):